Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ArQule

- PMLiVE

Merck & Co takes Alzheimer’s prospect into phase II/III trials

Developed to interrupt formation of amyloid plaques

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

Creston acquires DJM Digital Solutions

Deal includes 75 per cent of shares and an initial payment of £1.2m

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Eisai: Bucking the trend with R&D growth

PME’s emerging companies series continues with a firm that’s committed to research as it expands its commercial position

- PMLiVE

Roche’s Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

- PMLiVE

J&J, Lilly and Merck join forces on clinical trials

Will set up database to improve efficiency of industry-sponsored drug trials

Indegene acquires healthcare marketing services of Canada-based Aptilon

To provide clients with improved physician engagement strategies

- PMLiVE

Merck & Co stops development of Januvia, atorvastatin combo

Company spokesperson claims decision is for “business reasons”

- PMLiVE

New hope for castration-resistant prostate cancer

An unprecedented number of therapies have reached late-stage clinical trials or been approved over recent years targeting this disease with an unmet medical need

- PMLiVE

UK to use GSK’s Rotarix in rotavirus vaccination programme

Chosen ahead of Merck & Co’s RotaTeq

- PMLiVE

Good practice in cancer care recognised at UK awards

Sir Mike Richards honoured with lifetime achievement award at QiC Excellence in Oncology 2012

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links